SAN
DIEGO, Aug. 6, 2024 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused
on developing products to treat cancer and life threatening
infectious diseases, today announced that it will issue financial
results for its fiscal first quarter ended June 30, 2024, at 4:15 p.m. ET on Wednesday, August 14, 2024.
Management will host a conference call on Wednesday, August 14, 2024, at 4:30 p.m. ET
to review financial results and recent corporate developments.
Following management's formal remarks, there will be a question and
answer session.
Interested parties can register for the conference by navigating
to https://dpregister.com/sreg/10191735/fd44630e3d. Please
note that registered participants will receive their dial-in number
upon registration.
Interested parties without internet access or unable to
pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc.
conference call.
A replay of the call will be available approximately one hour
after the end of the call through September
14, 2024. The replay can be accessed via Aethlon
Medical's website or by dialing 1-877-344-7529 (domestic) or
1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay
conference ID number is 3788019.
About Aethlon and the Hemopurifier®
Aethlon
Medical is a medical therapeutic company focused on developing the
Hemopurifier, a clinical stage immunotherapeutic device which is
designed to combat cancer and life-threatening viral infections and
for use in organ transplantation. In human studies, the
Hemopurifier has demonstrated the removal of life-threatening
viruses and in pre-clinical studies, the Hemopurifier has
demonstrated the removal of harmful exosomes from biological
fluids, utilizing its proprietary lectin-based technology. This
action has potential applications in cancer, where exosomes may
promote immune suppression and metastasis, and in life-threatening
infectious diseases. The Hemopurifier is a U.S. Food and Drug
Administration (FDA) designated Breakthrough Device indicated for
the treatment of individuals with advanced or metastatic cancer who
are either unresponsive to or intolerant of standard of care
therapy, and with cancer types in which exosomes have been shown to
participate in the development or severity of the disease.
The Hemopurifier also holds an FDA Breakthrough Device
designation and an open Investigational Device Exemption (IDE)
application related to the treatment of life-threatening viruses
that are not addressed with approved therapies.
Additional information can be found
at www.AethlonMedical.com.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 that involve risks and uncertainties.
Statements containing words such as "may," "believe," "anticipate,"
"expect," "intend," "plan," "project," "will," "projections,"
"estimate," "potentially" or similar expressions constitute
forward-looking statements. Such forward-looking statements are
subject to significant risks and uncertainties and actual results
may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are
based upon Aethlon's current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Factors
that may contribute to such differences include, without
limitation, the Company's ability to raise additional capital if
and when needed, the Company's ability to successfully complete
development of the Hemopurifier and to successfully demonstrate the
utility of the Hemopurifier in patients with solid tumors in our
planned oncology clinical trials, the Company's ability work with
the requisite personnel and complete the next steps to facilitate
patient enrollment, the Company's ability to submit additional
studies and obtain the approval by the additional respective Ethics
Boards of interested clinical trial sites in India and in Australia, the Company's ability to recruit
patients for and manage its clinical trials, the Company's ability
to successfully manufacture the Hemopurifier in sufficient
quantities for its clinical trials, the Company's ability to
maintain its Nasdaq listing, and other potential risks. The
foregoing list of risks and uncertainties is illustrative but is
not exhaustive. Additional factors that could cause results to
differ materially from those anticipated in forward-looking
statements can be found under the caption "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended
March 31, 2024, and in the Company's
other filings with the Securities and Exchange Commission,
including its quarterly Reports on Form 10-Q. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Except as may be required by law, the
Company does not intend, nor does it undertake any duty, to update
this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-first-quarter-financial-results-and-host-conference-call-on-august-14-2024-302215555.html
SOURCE Aethlon Medical, Inc.